Brand Reference: Synthroid, Tirosint, Unithroid
| Metric | Verified Benchmark | Source |
|---|---|---|
| Levothyroxine Sodium (Synthetic L-Thyroxine T4) RxNorm Concept ID | 10582 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1120 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.50 / mo | 46 Zero-PHI Verified Patient Logs |
Synthetic levorotatory T4 prohormone bound >99.9% to thyroxine-binding globulin and deiodinated peripherally by type 1 and type 2 5-prime-deiodinases (DIO1/DIO2) into active triiodothyronine (T3), regulating nuclear TR-alpha/TR-beta mitochondrial oxidative phosphorylation.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Levothyroxine Sodium (Synthetic L-Thyroxine T4) (Synthroid / Tirosint / Unithroid, RxCUI 10582) at $0.1120 per unit, whereas walk-in chain pharmacies bill cash patients an average of $34.00 monthly—creating a 83% ($28.20/mo) wholesale arbitrage spread down to $5.80.
Systemic exposure to Levothyroxine Sodium (Synthetic L-Thyroxine T4) reflects 70%–80% fasting oral (chelated by calcium, iron, coffee) absorption kinetics and outer-ring deiodination to t3 or inner-ring dio3 to reverse-t3 plus hepatic conjugation, sustaining receptor engagement across a 6–7 days (allows stable single daily dosing) half-life window (4–6 weeks tsh steady-state equilibrium response profile).
Dosing protocols (25 mcg PO fasting QAM or 50 mcg PO QAM or 75 mcg PO QAM or 88–125 mcg PO QAM (1.6 mcg/kg/day full replacement)) balance efficacy (88.50% patient satisfaction across 46 logs) against absorption drop with morning coffee (19% of reports), palpitations if tsh < 0.2 (11% of reports), heat sensitivity (8% of reports), with strict avoidance in uncorrected adrenal cortical insufficiency (precipitates addisonian crisis); acute myocardial infarction.
Across 46 verified cash-pay logs, Levothyroxine Sodium (Synthetic L-Thyroxine T4) achieves a 88.50% Worth-It rating with out-of-pocket spend averaging $7.50/mo versus $34.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 25 mcg PO fasting QAM for Levothyroxine Sodium (Synthetic L-Thyroxine T4); monthly out-of-pocket dropped to $5.10 compared with $34.00 retail.
Completed 10 weeks on Levothyroxine Sodium (Synthetic L-Thyroxine T4) (50 mcg PO QAM). Zero notable side effects on steady dosing.
Consistent biomarker response on 75 mcg PO QAM Levothyroxine Sodium (Synthetic L-Thyroxine T4) sourced via Compounding ($6.73/mo cash pay without insurance prior authorization).